Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for Daniel Van Roy�
+14.86 (3.75%)
After Hours: 410.73 -0.26 (-0.06%)
Dec 17, 7:56PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 396.13 - 411.57
52 week 257.69 - 437.64
Open 398.40
Vol / Avg. 675,041.00/738,073.00
Mkt cap 40.39B
P/E 139.52
Div/yield     -
EPS 2.95
Shares 99.69M
Beta 0.85
Inst. own 73%
Feb 9, 2015
Q4 2014 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 3, 2014
Regeneron Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Dec 1, 2014
Regeneron Pharmaceuticals Inc at Deutsche Bank BioFEST
Nov 11, 2014
Regeneron Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 4, 2014
Q3 2014 Regeneron Pharmaceuticals Inc Earnings Release
Nov 4, 2014
Q3 2014 Regeneron Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 10.98% 20.16%
Operating margin 25.18% 36.11%
EBITD margin - 38.07%
Return on average assets 8.89% 16.87%
Return on average equity 13.00% 26.54%
Employees 2,340 -
CDP Score - -


777 Old Saw Mill River Road
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron develops new product candidate using VelociSuite technology platforms. Regeneron�s discovery platforms are designed to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through high-throughput production of genetically modified mice using the Company�s VelociGene technology to understand the role of these proteins in normal physiology, as well as in models of disease. The Company also has human monoclonal antibody technology, VelocImmune and cell line expression technology VelociMab. Regeneron�s antibody product candidates in clinical trials were developed using VelocImmune. The Company has three marketed products: EYLEA, ZALTRAP and ARCALYST.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 84
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 50
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 41
Bio & Compensation  - Reuters
Murray A. Goldberg Senior Vice President - Administration, Assistant Secretary
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 57
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Senior Vice President - Research and Development Sciences
Age: 57
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 54
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 54
Bio & Compensation  - Reuters